email article
Survival in advanced hormone receptor (HR)-positive breast cancer did not improve with the addition of a histone deacetylase (HDAC) inhibitor to standard endocrine therapy, according to a randomized trial.
Median progression-free survival (PFS) improved from 3.1 to 3.3 months and median overall survival (OS) from 21.7 to 23.4 months among patients who received entinostat plus the aromatase inhibitor (AI) exemestane. Neither difference reached statistical significance, despite a significant increase in lysine acetylation, which correlated in improved PFS in an earlier trial of the HDAC inhibitor. The short median progression-free survival and low overall response rate observed with an endocrine therapy backbone suggests that improved decision-making tools are required to help determine who may need chemotherapy versus alternative strategies in this setting, reported Roisin M. Connolly, MD, of University College Cork in Ireland, at the San Antonio Breast Cancer
Why Transdermal Drug Delivery Systems are Outweighing Advantages of Traditional Methods
Financialnewsmedia.com News Commentary
PALM BEACH, Fla., Dec. 15, 2020 /PRNewswire/ While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient s body? The simplest way is usually to administer the drug orally. Orally administered drugs can be conveniently stored and are portable, economical, noninvasive, and safe. No special training is required for the administration of these drugs as compared to topical formulations… but sometimes, simply taking a pill is not the best route for certain patients, which has given rise to alternative drug delivery systems. Transdermal delivery has benefit of simple application and may be a good alternative to oral delivery in cases when orally administrated drug causes serious side effects. The transdermal route has many
Immutep Operational Update - MarketWatch marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Efti clinical trial status updates
Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022
Sydney, AUSTRALIA, Dec. 15, 2020 (GLOBE NEWSWIRE) Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs.
Eftilagimod alpha (“efti”) Update
AIPAC - Phase IIb clinical trial
The Company presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, first Overall Survival (OS) data and is on track to report final overall survival data and overall response rate by mid calendar year 2021. Currently there are more than 66% of events compared to approx. 60% which were the basis of the OS data presented at the San Antonio Breast Cancer Conference.
email article
In the 21 months since the FDA granted accelerated approval to atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for locally advanced or metastatic PD-L1 positive triple-negative breast cancer (TNBC), Halle Moore, MD, of Cleveland Clinic Taussig Cancer Center in Ohio, has seen a definite uptake in use of the regimen. At our institution we routinely check upfront for PD-L1 expression, and unless it is contraindicated or a patient is going on a clinical trial, we recommend the combination in eligible patients, Moore said.
Even in that small time since the approval of that first immunotherapy, the field has already seen changes.